Orforglipron trial results: what the ATTAIN-1 data actually shows
Quick answer
The ATTAIN-1 trial (Jastreboff et al., 2025, NEJM) enrolled 3,127 adults with obesity or overweight plus a weight-related comorbidity but without type 2 diabetes, randomizing them to orforglipron doses of 6, 12, or 36 mg daily versus placebo over 72 weeks. The 36 mg dose produced approximately 12.4% mean weight reduction versus roughly 2% with placebo, with gastrointestinal events being the primary driver of discontinuation. Orforglipron is a non-peptide small molecule GLP-1 receptor agonist, meaning it does not require refrigeration or injection, which may expand access if it clears FDA review.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @chrisdaghermd actually say?
Dr. Dagher covered the ATTAIN-1 phase 3 trial for orforglipron, Eli Lilly's oral GLP-1 receptor agonist. He reported that the 36 mg dose produced "a 12.4% drop in weight" at 72 weeks, roughly 27 pounds, and that "almost 40% of the patients on the 36 milligram dose" lost more than 15% of their body weight. He noted cardiometabolic improvements including a "reduction in their inflammation by almost 50%." He also compared the drug to tirzepatide, citing "21-22% weight loss" for the injectable, and speculated orforglipron could seek FDA approval around 2026. His main thesis: this is the first oral pill with genuinely effective weight loss results.
Does the science back this up?
Mostly, yes. The ATTAIN-1 trial data, published in the New England Journal of Medicine in 2025, largely supports what he said. The 36 mg orforglipron arm did achieve approximately 12.4% mean body weight reduction versus around 2% for placebo at 72 weeks. That is a clinically meaningful difference. The cardiometabolic signal, including improvements in lipids, blood pressure, and C-reactive protein, is real and consistent with what you see across the GLP-1 drug class.
Where things get slightly fuzzy is the inflammation claim. A "50% reduction in inflammation" sounds dramatic, but C-reactive protein reductions in GLP-1 trials are partly driven by weight loss itself, not a direct anti-inflammatory drug effect. That distinction matters when you're talking to patients about why this drug works. The ATTAIN-1 investigators (Jastreboff et al., 2025, NEJM) were careful to note this, even if a TikTok summary can't be expected to go that deep.
What did they get wrong (or right)?
The tirzepatide comparison deserves scrutiny. Dagher says injections are "probably more effective" and cites "21-22% weight loss" for tirzepatide at roughly the same time interval. That figure is in the right neighborhood for the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), where the highest dose hit around 20.9% at 72 weeks. But comparing two different drugs across two different trials, with different populations, different baseline weights, and different designs, is not a clean apples-to-apples comparison. He hedges appropriately with the word "roughly," but listeners may walk away thinking orforglipron is simply the inferior, cheaper option. The reality is more complicated.
His framing that this is "the first oral pill with really effective weight loss" also warrants a small asterisk. Oral semaglutide (Rybelsus, later Wegovy oral formulation) exists, though its efficacy data at approved doses has historically lagged behind injectable semaglutide. Orforglipron's oral bioavailability mechanism differs and appears more dose-consistent, so the claim has merit, but calling it the unambiguous first is slightly overstated.
Credit where it is due: he correctly identifies ATTAIN-1 as a randomized placebo-controlled trial across multiple countries, accurately reports the headline efficacy numbers, and honestly acknowledges the injection-versus-pill trade-off without overselling either option.
What should you actually know?
Orforglipron is not approved yet. Phase 3 data is the step before FDA submission, and regulatory review takes time. A 2026 approval is plausible based on Lilly's stated timeline, but that is not guaranteed. The drug still needs to clear the full regulatory process.
The 12.4% average weight loss figure is a mean. That means half the patients lost less. Patient-level variation in GLP-1 response is real and driven by factors including adherence, baseline metabolic health, diet, and genetic differences in GLP-1 receptor expression. "Almost 40% lost over 15%" is genuinely impressive, but it also means the majority did not hit that threshold.
Side effect profile matters. Like other GLP-1 agonists, orforglipron's trial showed gastrointestinal adverse events, nausea, vomiting, diarrhea, as the most common reasons for discontinuation. Dagher did not cover this in detail, which is a notable omission for a clinical summary aimed at patients weighing treatment options.
If you are considering any GLP-1 therapy, the conversation belongs with a clinician who has access to your full health history, not a 60-second video, including this one.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Orforglipron trial results: what the ATTAIN-1 data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Orforglipron trial results: what the ATTAIN-1 data actually shows should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The ATTAIN-1 trial (Jastreboff et al.
FormBlends verdict
The ATTAIN-1 trial (Jastreboff et al., 2025, NEJM) enrolled 3,127 adults with obesity or overweight plus a weight-related comorbidity but without type 2 diabetes, randomizing them to orforglipron doses of 6, 12, or 36 mg daily versus placebo over 72 weeks. The 36 mg dose produced approximately 12.4% mean weight reduction versus roughly 2% with placebo, with gastrointestinal events being the primary driver of discontinuation. Orforglipron is a non-peptide small molecule GLP-1 receptor agonist, meaning it does not require refrigeration or injection, which may expand access if it clears FDA review.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The ATTAIN-1 trial (Jastreboff et al., 2025, NEJM) enrolled 3,127 adults with obesity or overweight plus a weight-related comorbidity but without type 2 diabetes, randomizing them to orforglipron doses of 6, 12, or 36 mg daily versus placebo over 72 weeks. The 36 mg dose produced approximately 12.4% mean weight reduction versus roughly 2% with placebo, with gastrointestinal events being the primary driver of discontinuation. Orforglipron is a non-peptide small molecule GLP-1 receptor agonist, meaning it does not require refrigeration or injection, which may expand access if it clears FDA review.
- ATTAIN-1 (Jastreboff et al., 2025, NEJM): orforglipron 36 mg produced approximately 12.4% mean weight loss versus roughly 2% for placebo at 72 weeks in non-diabetic adults with obesity.
- About 37-40% of the highest-dose group lost more than 15% of body weight, but that also means the majority of patients did not reach that threshold.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- ATTAIN-1 (Jastreboff et al., 2025, NEJM): orforglipron 36 mg produced approximately 12.4% mean weight loss versus roughly 2% for placebo at 72 weeks in non-diabetic adults with obesity.
- About 37-40% of the highest-dose group lost more than 15% of body weight, but that also means the majority of patients did not reach that threshold.
- Orforglipron is a non-peptide small molecule, which means no injection and no refrigeration required, a real practical difference from semaglutide or tirzepatide.
- Gastrointestinal side effects, primarily nausea, vomiting, and diarrhea, were the main reasons for discontinuation in ATTAIN-1, a detail the video did not address.
- Comparing orforglipron to tirzepatide across separate trials is not a clean comparison; different populations, designs, and baselines make the efficacy gap harder to quantify than a simple percentage difference.
- Orforglipron is still investigational as of mid-2025. A 2026 FDA approval is Lilly's stated goal, not a confirmed timeline.
- Cardiometabolic improvements in the trial, including lipid and blood pressure changes, are consistent with GLP-1 class effects and partly mediated by weight loss itself, not a separate drug mechanism.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dagher MD · TikTok creator
2.6K views on this video
ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, orforglipron 36 mg, lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo The most common adverse events were nausea, constipation, diarrhea, vomiting, dyspepsia#greenscreen
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dagher MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.